Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)

Antiviral Therapy

Volumn 19, Issue 2, 2014, Pages 191-200

  Wohl, David A ^a   Orkin, Chloe ^b   Doroana, Manuela ^c   Pilotto, José H ^d   Sungkanuparph, Somnuek ^e   Yeni, Patrick ^f   Vanveggel, Simon ^g   Deckx, Henri ^g   Boven, Katia ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d HOSPITAL GERAL DE FORTALEZA   (Brazil)

^e MAHIDOL UNIVERSITY   (Thailand)

^f BICHAT HOSPITAL   (France)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RILPIVIRINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; NITRILE; PYRIMIDINE DERIVATIVE; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ETHNICITY; FEMALE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRIMIDINES; RILPIVIRINE; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84898643563     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2721     Document Type: Article

References (39)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
2. Kwan CK, Eckhardt B, Baghdadi J, Aberg JA. Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, NY. AIDS Res Hum Retroviruses 2012; 28:1025-1032.
3. Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. AIDS 2012; 26:253-262.
4. Vescini F, Cozzi-Lepri A, Borderi M, et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr 2011; 58:163-172.
5. Kim JH, Gandhi V, Psevdos G, et al. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses 2012; 28:235-241.
6. Viard JP, Souberbielle JC, Kirk O, et al. EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25:1305-1315.
7. Adeyemi OM, Agniel D, French AL, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr 2011; 57:197-204.
8. Conesa-Botella A, Florence E, Lynen L, et al. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 2010; 7:40.
9. Fox J, Peters B, Prakash M, et al. Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses 2011; 27:29-34.
10. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-1928.
11. Wasserman P, Rubin DS. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIVinfected men under care. AIDS Patient Care STDS 2010; 24:223-227.
12. Tsiaras WG, Weinstock MA. Factors influencing vitamin D status. Acta Derm Venereol 2011; 91:115-124.
13. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 2011; 31:48-54.
14. Crutchley RD, Gathe J, Mayberry C, et al. Risk factors for vitamin D deficiency in HIV-infected patients in the South Central United States. AIDS Res Hum Retroviruses 2012; 28:454-459.
15. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
16. Lake JE, Adams JS. Vitamin D in HIV-infected patients. Curr HIV/AIDS Rep 2011; 8:133-141.
17. Allavena C, Delpierre C, Cuzin L, et al. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother 2012; 67:2222-2230.
18. Fux CA, Baumann S, Furrer H, Mueller NJ. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the nonnucleoside reverse transcriptase inhibitor class? AIDS 2011; 25:876-878.
19. Welz T, Childs K, Post FA. Do nevirapine and efavirenz affect vitamin D homeostasis similarly? AIDS 2011; 25:875-876.
20. Pasquet A, Viget N, Ajana F, et al. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS 2011; 25:873-874.
21. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1375-1382.
22. Mueller NJ, Fux CA, Ledergerber B, et al. Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24:1127-1134.
23. Rodríguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009; 25:9-14.
24. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15:425-429.
25. Lattuada E, Lanzafame M, Zoppini G, et al. No influence of nevirapine on vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses 2009; 25:849-850.
26. Gyllensten K, Josephson F, Lidman K, Sääf M. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS 2006; 20:1906-1907.
27. Herzmann C, Arastéh K. Efavirenz-induced osteomalacia. AIDS 2009; 23:274-275.
28. Rockstroh J, Stoehr A, Duiculescu D, et al. Analysis of vitamin D and parathyroid hormone in the SENSE trial: etravirine versus efavirenz in treatment-naive HIV-1 infected patients. Antiviral Therapy 2010; 15 Suppl 4:A42.
29. Molina J-M, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatmentnaive adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
30. EDURANT. 25mg film-coated tablets. Summary of product characteristics. Janssen-Cilag International NV, November 2011. (Updated December 2013. Accessed 28 January 2013). Available from http://www.medicines.org.uk/EMC/medicine/25490/SPC/Edurant+25+mg/.
31. EDURANT™ (rilpivirine) tablets. Full prescribing information. Janssen, Inc., 2011. (Updated June 2013. Accessed 28 January 2013). Available from http://www.edurant-info.com/sites/default/files/EDURANT-PI.pdf.
32. National Institutes of Health (NIH), Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D, 24 June 2011. (Accessed 28 January 2013). Available from http://ods.od.nih.gov/factsheets/vitamind/.
33. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007; 85:860-868.
34. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713-716.
35. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010; 340:b5664.
36. Mehta S, Mugusi FM, Spiegelman D, et al. Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania. AIDS Patient Care STDS 2011; 25:579-585.
37. Tebas P, Henry K, Nelson M, et al. Results from the pooled DEXA substudies of the double-blind, randomised, Phase III trials comparing rilpivirine (RPV,TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. Antivir Ther 2011; 16 Suppl 2:A19.
38. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718.
39. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8:164-172.